RGA:NYSEReinsurance Group of America, Incorporated Analysis
Data as of 2026-08-03 - not real-time
$236.85
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Reinsurance Group of America (RGA) is trading at $236.85, comfortably above its 20‑day ($235.67), 50‑day ($219.23) and 200‑day ($206.59) simple moving averages, signaling a sustained bullish trend. The stock’s RSI sits at 58.6, indicating modest momentum without being overbought, while the MACD histogram is slightly negative, suggesting a short‑term bearish tilt but not enough to offset the broader uptrend. Volatility remains elevated at roughly 24% over the past 30 days, yet the beta of 0.30 points to low systematic risk relative to the market. Fundamentally, RGA delivers a compelling value story: a trailing P/E of 12.9 versus an industry average of 18.0, a forward P/E of just 8.1, and a price‑to‑book of 1.17, all implying the stock is undervalued. Revenue growth is robust at 23.5% YoY, with Q1 sales up 21.6% to $6.49 bn, and EPS is projected to jump from $18.40 trailing to $29.25 forward, underscoring strong earnings momentum. The dividend yield of 1.57% coupled with a modest 20% payout ratio supports a sustainable income stream. Recent accolades—including being named “Reinsurer of the Year” – and a refreshed leadership team reinforce confidence in execution, while analysts collectively rate the stock as a “Buy” with a median target of $269, implying roughly 10% upside.
Given the combination of technical strength, attractive valuation metrics, solid growth, and a low‑beta profile, RGA presents a balanced risk‑reward proposition. The upside potential is modest but credible, and the dividend adds a defensive layer. However, the elevated short‑term volatility and a bearish MACD signal suggest caution on immediate entries, though the broader fundamentals remain resilient.
Given the combination of technical strength, attractive valuation metrics, solid growth, and a low‑beta profile, RGA presents a balanced risk‑reward proposition. The upside potential is modest but credible, and the dividend adds a defensive layer. However, the elevated short‑term volatility and a bearish MACD signal suggest caution on immediate entries, though the broader fundamentals remain resilient.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 8/10
Key Factors
- Price above key moving averages indicating bullish momentum
- Upcoming earnings release with recent Q1 beat
- Technical support at $220.33 and modest upside potential
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Undervalued valuation metrics (P/E, forward P/E) relative to peers
- Strong revenue and EPS growth outlook
- Sustainable dividend with low payout ratio
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Diversified global reinsurance footprint reducing concentration risk
- Award‑winning market position and leadership stability
- Low beta and solid balance sheet supporting resilience
Key Metrics & Analysis
Financial Health
Revenue Growth23.50%
Profit Margin4.92%
P/E Ratio12.9
ROE9.90%
ROA0.85%
Debt/Equity45.61
P/B Ratio1.2
Op. Cash Flow$5.5B
Free Cash Flow$4.8B
Industry P/E18.0
Technical Analysis
TrendBullish
RSI58.6
Support$220.33
Resistance$245.00
MA 20$235.67
MA 50$219.23
MA 200$206.59
MACDBearish
VolumeDecreasing
Fear & Greed Index92.88
Valuation
Fair Value$2,420.46
Target Price$261.78
Upside/Downside10.52%
GradeUndervalued
TypeBlend
Dividend Yield1.57%
Risk Assessment
Beta0.30
Volatility23.98%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.